21.4K(top 0.1%)
papers
391.1K(top 0.1%)
citations
189(top 0.1%)
h-index
368(top 0.1%)
g-index
24.3K
all documents
423.0K
doc citations
16.3K
citing journals
8.8K
times ranked

Top Articles

#TitleJournalYearCitations
1Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine20097,606
2Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialLancet, The20105,899
3Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialLancet, The20183,542
4Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialLancet, The20173,224
5Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine20133,181
6First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung CancerNew England Journal of Medicine20142,808
7Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialLancet, The20172,771
8Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialLancet Oncology, The20181,816
9Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialLancet, The20171,749
10JENDL-4.0: A New Library for Nuclear Science and EngineeringJournal of Nuclear Science and Technology20111,716
11Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 updateHepatology International20171,537
12International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy studyLancet, The20181,487
13Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyLancet Oncology, The20201,363
14All-solid-state Z-scheme in CdS–Au–TiO2 three-component nanojunction systemNature Materials20061,266
15Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III TrialJournal of Clinical Oncology20201,255
16Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaNew England Journal of Medicine20181,253
17Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncology, The20191,202
18Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid CarcinomaJAMA Oncology20161,192
19High performance plasma amyloid-β biomarkers for Alzheimer’s diseaseNature20181,180
20Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumoursJournal of Pathology20141,151
21High Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-weighted MR Images: Relationship with Increasing Cumulative Dose of a Gadolinium-based Contrast MaterialRadiology20141,112
22Role of oxygen vacancy in the plasma-treated TiO2 photocatalyst with visible light activity for NO removalJournal of Molecular Catalysis A20001,110
23The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)Hypertension Research20191,047
24Regulation and function of ascorbate peroxidase isoenzymesJournal of Experimental Botany20021,021
25CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc− and Thereby Promotes Tumor GrowthCancer Cell20111,020
26Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementiaNature20111,016
27Insights into Land Plant Evolution Garnered from the Marchantia polymorpha GenomeCell2017973
28Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinomaHepatology International2010944
29Eight Calves Cloned from Somatic Cells of a Single AdultHepatology International1998932
30Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian CancerJournal of Clinical Oncology2015924
31The Chemokine Superfamily RevisitedImmunity2012914
32Apalutamide for Metastatic, Castration-Sensitive Prostate CancerNew England Journal of Medicine2019904
33Galactinol and Raffinose Constitute a Novel Function to Protect Plants from Oxidative Damage    Plant Physiology2008888
34Aspects of Grand Unified Models with Softly Broken SupersymmetryProgress of Theoretical Physics1982767
35Neonicotinoids: insecticides acting on insect nicotinic acetylcholine receptorsTrends in Pharmacological Sciences2001760
36Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trialLancet, The2017753
37Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With SorafenibJAMA Oncology2020746
38Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung CancerJAMA Oncology2018735
39Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular CarcinomaJournal of Clinical Oncology2020723
40Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trialLancet, The2009685
41Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III TrialJournal of Clinical Oncology2013678
42Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 studyLancet Oncology, The2014678
43Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III TrialJournal of Clinical Oncology2012676
44Cancer classification using the Immunoscore: a worldwide task forceJournal of Translational Medicine2012676
45Visible-light-active titanium oxide photocatalyst realized by an oxygen-deficient structure and by nitrogen dopingApplied Catalysis B: Environmental2003668
46Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatmentProceedings of the National Academy of Sciences of the United States of America2013658
47NASH limits anti-tumour surveillance in immunotherapy-treated HCCNature2021649
48Design concepts for the Cherenkov Telescope Array CTA: an advanced facility for ground-based high-energy gamma-ray astronomyExperimental Astronomy2011640
49Clinical features of isolated noncompaction of the ventricular myocardiumJournal of the American College of Cardiology1999636
50Mordred: a molecular descriptor calculatorJournal of Cheminformatics2018622